ReviewAnnals of hematology2026
GFI1B mutations define an emerging form of inherited thrombocytopenia: insights from a case report and literature review.
Review in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Inherited thrombocytopenias (ITs) constitute a heterogeneous group of congenital bleeding disorders caused by defects in over 50 genes that predominantly affect platelet production. GFI1B has recently emerged as a critical transcriptional regulator of megakaryocyte and erythroid differentiation. Its dysfunction underlies a rare autosomal dominant form of IT, which usually results in moderately reduced platelet counts. We report an adult male with lifelong severe thrombocytopenia (platelet count range 10–20 × 10⁹/L) and recurrent bleeding episodes since early childhood. Comprehensive molecular analysis identified a heterozygous NM_001377304.1:c.814 + 1G > A variant in the zinc finger region of GFI1B, resulting in a frameshift and premature truncation. The proband exhibited hallmark features of this IT subtype, including α‑granule deficiency and persistent CD34 expression in megakaryocytes and platelets. Based on preclinical evidence, the patient initially received eltrombopag, followed later by romiplostim, achieving a partial platelet response and improvement in bleeding symptoms. Familial analysis revealed marked variability in platelet counts and bleeding phenotypes among carriers of the same variant, including the patient’s mother, highlighting that clinical outcomes cannot be reliably predicted from genotype alone. A literature review confirmed considerable phenotypic heterogeneity in GFI1B-related thrombocytopenia, indicating that variant type and location only partially account for disease severity. This report represents the first in-human use of thrombopoietin receptor agonists in GFI1B-related thrombocytopenia. It underscores the challenges in diagnosing and managing ITs and emphasizes the importance of early genetic testing. Further studies are needed to elucidate the molecular determinants of phenotypic variability and to develop targeted therapeutic strategies for affected patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.